

RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF**Patent number:** JP2003519470 (T)**Publication date:** 2003-06-24**Inventor(s):****Applicant(s):****Classification:**

- international:

C12N15/09; A61K38/00; A61K39/395; A61K45/00; A61P1/04;
 A61P1/16; A61P7/00; A61P11/00; A61P11/06; A61P17/00;
 A61P19/02; A61P19/10; A61P21/00; A61P25/00; A61P29/00;
 A61P35/00; A61P35/02; A61P37/02; A61P37/04; A61P37/08;
 C07K5/113; C07K16/18; C07K16/28; C07K16/46; C07K19/00;
 C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/02;
 C12N15/09; A61K38/00; A61K39/395; A61K45/00; A61P1/00;
 A61P7/00; A61P11/00; A61P17/00; A61P19/00; A61P21/00;
 A61P25/00; A61P29/00; A61P35/00; A61P37/00; C07K5/00;
 C07K16/18; C07K16/46; C07K19/00; C12N1/15; C12N1/19;
 C12N1/21; C12N5/10; C12P21/02; (IPC1-7): C12N15/09;
 A61K38/00; A61K39/395; A61K45/00; A61P1/04; A61P1/16;
 A61P7/00; A61P11/00; A61P11/06; A61P17/00; A61P19/02;
 A61P19/10; A61P21/00; A61P25/00; A61P29/00; A61P35/00;
 A61P35/02; A61P37/02; A61P37/04; A61P37/08; C07K16/18;
 C07K16/46; C07K19/00; C12N1/15; C12N1/19; C12N1/21;
 C12N5/10; C12P21/02

- european:

C07K5/10C; C07K16/28R

Application number: JP20010501630T 20000608**Priority number(s):** US19990328296 19990608; WO2000US15749 20000608**Also published as:**

WO0075348 (A1)
 ZA200110215 (A)
 US6843989 (B1)
 US6838261 (B1)
 US6946129 (B1)

more >>

Abstract not available for JP 2003519470 (T)

Abstract of correspondent: **WO 0075348 (A1)**

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Data supplied from the esp@cenet database — Worldwide